Acuta Capital Partners, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Acuta Capital Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$37.38 - $49.47 $9.53 Million - $12.6 Million	-255,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$39.79 - $67.01 $1.95 Million - $3.28 Million	49,000 Added 23.79%	255,000 $11.2 Million
Q1 2019 May 14, 2019	BUY	$34.52 - $53.29 $638,620 - $985,865	18,500 Added 9.87%	206,000 $10.6 Million
Q4 2018 Feb 14, 2019	BUY	$29.75 - $42.9 $1.64 Million - $2.36 Million	55,000 Added 41.51%	187,500 $6.93 Million
Q3 2018 Nov 07, 2018	SELL	$32.79 - $43.0 $901,725 - $1.18 Million	-27,500 Reduced 17.19%	132,500 $4.98 Million
Q2 2018 Aug 15, 2018	BUY	$23.62 - $42.29 $3.78 Million - $6.77 Million	160,000 New	160,000 $6.32 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.